NASDAQ$GRCE
Grace Therapeutics Inc · Q1 2026 earnings
Q1 2026 earnings · · Before market open · Investor relations
Briefing
Grace Therapeutics reported Q1 2026, net loss of $3.36B, diluted EPS of $9.00.
For Q1 2026, Grace Therapeutics reported a net loss of $3.36B, diluted EPS was $9.00. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Net loss $3.36B.
- Diluted EPS $9.00.
- Grace Therapeutics highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Acasti Pharma · Revenue · Quarterly
$0
Forward guidance
The release discusses Grace Therapeutics's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Grace Therapeutics cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q1 2026.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q1 2026
+0.7%
Avg return
Earnings day
+31.8%
Avg return
5 days after
+22.6%
Avg return
30 days after
44%
7 / 16 earnings
Positive
+12.3%
Q3 2022
Best reaction
-5.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +2.3% | +4.3% | +9.2% | |
| Q1 2026 | +3.5% | +5.2% | +3.9% | |
| Q4 2025 | -2.3% | -1.0% | +11.7% | |
| Q4 2024 | +1.6% | -3.6% | +9.4% | |
| Q3 2025 | +0.0% | -1.7% | -37.4% | |
| Q1 2025 | -1.0% | -11.7% | -16.5% | |
| Q2 2025 | +3.8% | -0.9% | +12.2% | |
| Q3 2024 | -1.2% | +34.7% | +38.8% | |
| Q2 2024 | -2.0% | -2.3% | -4.5% | |
| Q1 2024 | -1.9% | +17.0% | -22.0% | |
| Q4 2023 | -5.3% | -7.0% | -25.7% | |
| Q3 2022 | +12.3% | -1.6% | -28.1% | |
| Q2 2022 | -3.6% | -14.0% | -30.0% | |
| Q4 2022 | -3.2% | +491.2% | +471.7% | |
| Q3 2021 | +7.0% | +3.5% | -10.5% | |
| Q1 2022 | +1.7% | -3.4% | -20.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro